Other
Dec 2023Science reported backlash from the Psychiatric Genomics Consortium over Orchid’s use of research data for embryo polygenic screening; the group said its data-use terms were violated, and Orchid denied improper use.
SourceAI-powered EHR for independent mental health professionals
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Orchid is a San Francisco-based reproductive technology company offering CAP/CLIA-certified whole-genome embryo screening for IVF and preconception genetic testing to help prospective parents assess monogenic and polygenic disease risk.
Primary product
Whole Genome Embryo Screening / Embryo Report (PGT-WGS)
Founded
2020
Headquarters
San Francisco, California, United States
Team size
20-30
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Reproductive genetics / IVF embryo screening / clinical genetic testing
Offices
Open Positions
0 jobs at Orchid
No open positions
Check back later for new openings